INT J LAB HEMATOL:突尼斯人丙酮酸激酶缺乏的分子基础

2017-04-23 MedSci MedSci原创

丙酮酸激酶(PK)缺乏症是世界上最常见的遗传性非皮质红细胞溶血性贫血之一,临床表现为从轻度到重度溶血。然而,调查表明突尼斯人缺乏这种酶病症。研究人员在此项研究中报告突尼斯案例中PK缺陷的调查,包括不明原因溶血性贫血的实验室生物学分析。

近日,国际杂志INT J LAB HEMATOL上在线发表一项关于突尼斯人丙酮酸激酶缺乏的分子基础的研究,阐述了影响PKLR基因编码和非编码区的新发突变。

丙酮酸激酶(PK)缺乏症是世界上最常见的遗传性非皮质红细胞溶血性贫血之一,临床表现为从轻度到重度溶血。然而,调查表明突尼斯人缺乏这种酶病症。研究人员在此项研究中报告突尼斯案例中PK缺陷的调查,包括不明原因溶血性贫血的实验室生物学分析。

235名患有不明原因溶血性贫血的患者被发送到该团队的实验室,以调查红细胞遗传疾病。研究通过标准方法测定红细胞酶活性,并通过DNA测序进行分子分析。 同时使用特定的软件进行突变效应和分子建模的进行解释。

研究人员发现六种不同的PKLR突变(c.966-1G> T; c.965 + 1G> A; c.721G> T; c.1163C> A; c.1456C> T; c.1537T> A),其中四个是第一次描述。通过三维结构分析研究了新型错义突变的基因型 - 表型相关性。

这项研究提供突尼斯人PK缺陷的重要数据。之后可能需要对新生儿进行大面积筛查来确定PK突变的频谱,并确定潜在缺陷患者。

原始出处:

M. Jaouani, L. Manco, M. S. et.al. Molecular basis of pyruvate kinase deficiency among Tunisians: description of new mutations affecting coding and noncoding regions in the PKLR gene. (pages 223–231) Abbes Version of Record online: 30 JAN 2017 | DOI: 10.1111/ijlh.12610

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2058230, encodeId=f7ef2058230dd, content=<a href='/topic/show?id=265e2094875' target=_blank style='color:#2F92EE;'>#丙酮酸激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20948, encryptionId=265e2094875, topicName=丙酮酸激酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Sun Jul 02 17:00:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771088, encodeId=c7311e71088b0, content=<a href='/topic/show?id=19b63159120' target=_blank style='color:#2F92EE;'>#分子基础#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31591, encryptionId=19b63159120, topicName=分子基础)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=640638200482, createdName=drwjr, createdTime=Thu Dec 14 10:00:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317280, encodeId=ffd1131e280e5, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Apr 24 15:00:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495957, encodeId=0507149595ebd, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Mon Apr 24 15:00:00 CST 2017, time=2017-04-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2058230, encodeId=f7ef2058230dd, content=<a href='/topic/show?id=265e2094875' target=_blank style='color:#2F92EE;'>#丙酮酸激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20948, encryptionId=265e2094875, topicName=丙酮酸激酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Sun Jul 02 17:00:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771088, encodeId=c7311e71088b0, content=<a href='/topic/show?id=19b63159120' target=_blank style='color:#2F92EE;'>#分子基础#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31591, encryptionId=19b63159120, topicName=分子基础)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=640638200482, createdName=drwjr, createdTime=Thu Dec 14 10:00:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317280, encodeId=ffd1131e280e5, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Apr 24 15:00:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495957, encodeId=0507149595ebd, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Mon Apr 24 15:00:00 CST 2017, time=2017-04-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2058230, encodeId=f7ef2058230dd, content=<a href='/topic/show?id=265e2094875' target=_blank style='color:#2F92EE;'>#丙酮酸激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20948, encryptionId=265e2094875, topicName=丙酮酸激酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Sun Jul 02 17:00:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771088, encodeId=c7311e71088b0, content=<a href='/topic/show?id=19b63159120' target=_blank style='color:#2F92EE;'>#分子基础#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31591, encryptionId=19b63159120, topicName=分子基础)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=640638200482, createdName=drwjr, createdTime=Thu Dec 14 10:00:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317280, encodeId=ffd1131e280e5, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Apr 24 15:00:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495957, encodeId=0507149595ebd, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Mon Apr 24 15:00:00 CST 2017, time=2017-04-24, status=1, ipAttribution=)]
    2017-04-24 fengyi812
  4. [GetPortalCommentsPageByObjectIdResponse(id=2058230, encodeId=f7ef2058230dd, content=<a href='/topic/show?id=265e2094875' target=_blank style='color:#2F92EE;'>#丙酮酸激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20948, encryptionId=265e2094875, topicName=丙酮酸激酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Sun Jul 02 17:00:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771088, encodeId=c7311e71088b0, content=<a href='/topic/show?id=19b63159120' target=_blank style='color:#2F92EE;'>#分子基础#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31591, encryptionId=19b63159120, topicName=分子基础)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=640638200482, createdName=drwjr, createdTime=Thu Dec 14 10:00:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317280, encodeId=ffd1131e280e5, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Apr 24 15:00:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495957, encodeId=0507149595ebd, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Mon Apr 24 15:00:00 CST 2017, time=2017-04-24, status=1, ipAttribution=)]
    2017-04-24 redcrab